Drug Type Synthetic peptide, Cyclic Peptide |
Synonyms Cefilavancin, RD-1792, TD-1792 |
Target |
Action inhibitors |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC87H95Cl3N16O28S2 |
InChIKeyOGUAFUAJSPORAH-KHCCTVBNSA-N |
CAS Registry722454-12-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Complicated skin and soft tissue infection | Phase 3 | Georgia | 27 Dec 2015 | |
| Gram-Positive Bacterial Infections | Phase 3 | - | - | |
| Gram-Positive Bacterial Infections | Phase 3 | - | - | |
| Skin and skin structure infections | Phase 3 | - | - | |
| Skin and skin structure infections | Phase 3 | - | - | |
| Complicated skin and skin structure infection | Phase 2 | United States | 01 Dec 2006 | |
| Staphylococcal Skin Infections | Phase 2 | United States | 01 Dec 2006 |






